CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2010-11-26): Novel protease inhibitor active against hepatitis C

Drug & Device Development

Novel protease inhibitor active against hepatitis C

Last Updated: 2010-11-26 9:01:47 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The protease inhibitor BI201335 is a promising treatment constituent in patients with chronic hepatitis C virus (HCV) genotype-1 infection, researchers report in a November online paper in Hepatology.

The condition affects many millions worldwide, and as Dr. Michael P. Manns told Reuters Health by email, "BI201335 is a potent second-generation NS3/4A HCV protease inhibitor with once-daily dosing and a so far good safety profile, which is under promising further clinical development."

Dr. Manns of Hannover Medical School, Germany, and colleagues note that genotype-1 HCV is the most prevalent and difficult-to-treat HCV subtype. Standard care is with pegylated interferon alfa and ribavirin, but more than 50% of patients don't respond or relapse.

Inhibition of the NS3/NS4A HCV protease has been shown to suppress viral replication, and in the current study the researchers sought to assess the utility of BI201335 in this regard.

The team randomized 34 treatment-naive patients to monotherapy with placebo or BI201335 at 20 to 240 mg once-daily for 14 days. This was followed by 14 days of use along with pegylated interferon alfa/ribavirin.

Active monotherapy induced a rapid, dose-dependent decrease in plasma HCV RNA from baseline in all patients. Subsequently, viral load breakthrough was common. Addition of pegylated interferon alfa/ribavirin led to continuous viral load reductions in most patients.

A further 19 treatment-experienced patients also received combination treatment with 48 to 240 mg BI201335 for 28 days. Viral loads fell and breakthroughs were seen in only 3 of these patients.

In light of these and other findings, the researchers conclude that the data support "the investigation of different treatment regimens testing doses from 120 mg to 480 mg daily in phase IIb trials."

SOURCE: http://link.reuters.com/huv66q

Hepatology 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.